Back to Search Start Over

Extracorporeal Photopheresis Improves Graft Survival in a Full-Mismatch Rat Model of Kidney Transplantation.

Authors :
Piñeiro GJ
Lazo-Rodriguez M
Ventura-Aguiar P
Ramirez-Bajo MJ
Banon-Maneus E
Lozano M
Cid J
Hierro-Garcia N
Cucchiari D
Revuelta I
Montagud-Marrahi E
Palou E
Bayés-Genís B
Campistol JM
Diekmann F
Rovira J
Source :
Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2023 Jan 12; Vol. 36, pp. 10840. Date of Electronic Publication: 2023 Jan 12 (Print Publication: 2023).
Publication Year :
2023

Abstract

Extracorporeal photopheresis (ECP) is an immunomodulatory therapy based on the infusion of autologous cellular products exposed to ultraviolet light (UV) in the presence of a photosensitizer. The study evaluates the ECP efficacy as induction therapy in a full-mismatch kidney transplant rat model. Dark Agouti to Lewis (DA-L) kidney transplant model has been established. ECP product was obtained from Lewis rat recipients after DA kidney graft transplantation (Lew <superscript>DA</superscript> ). Leukocytes of those Lew <superscript>DA</superscript> rats were exposed to 8-methoxy psoralen, and illuminated with UV-A. The ECP doses assessed were 10 × 10 <superscript>6</superscript> and 100 × 10 <superscript>6</superscript> cells/time point. Lewis recipients received seven ECP infusions. DA-L model was characterized by the appearance of donor-specific antibodies (DSA) and kidney function deterioration from day three after kidney transplant. The dysfunction progressed rapidly until graft loss (6.1 ± 0.5 days). Tacrolimus at 0.25 mg/kg prolonged rat survival until 11.4 ± 0.7 days ( p = 0.0004). In this context, the application of leukocytes from LewDA sensitized rats accelerated the rejection (8.7 ± 0.45, p = 0.0012), whereas ECP product at high dose extended kidney graft survival until 26.3 ± 7.3 days, reducing class I and II DSA in surviving rats. ECP treatment increases kidney graft survival in full-mismatch rat model of acute rejection and is a suitable immunomodulatory therapy to be explored in kidney transplantation.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Piñeiro, Lazo-Rodriguez, Ventura-Aguiar, Ramirez-Bajo, Banon-Maneus, Lozano, Cid, Hierro-Garcia, Cucchiari, Revuelta, Montagud-Marrahi, Palou, Bayés-Genís, Campistol, Diekmann and Rovira.)

Details

Language :
English
ISSN :
1432-2277
Volume :
36
Database :
MEDLINE
Journal :
Transplant international : official journal of the European Society for Organ Transplantation
Publication Type :
Academic Journal
Accession number :
36713113
Full Text :
https://doi.org/10.3389/ti.2023.10840